Intellia Therapeutics, Inc.

NASDAQ:NTLA

25.15 (USD) • At close June 14, 2024
Bedrijfsnaam Intellia Therapeutics, Inc.
Symbool NTLA
Munteenheid USD
Prijs 25.15
Beurswaarde 2,426,356,310
Dividendpercentage 0%
52-weken bereik 19.37 - 46.9
Industrie Biotechnology
Sector Healthcare
CEO Dr. John M. Leonard M.D.
Website https://www.intelliatx.com

An error occurred while fetching data.

Over Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A

Vergelijkbare Aandelen

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

39.05 USD

Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

MRTX

58.7 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

45.3 USD

Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

CYTK

53.93 USD

Blueprint Medicines Corporation logo

Blueprint Medicines Corporation

BPMC

105.55 USD

Karuna Therapeutics, Inc. logo

Karuna Therapeutics, Inc.

KRTX

329.83 USD

CureVac N.V. logo

CureVac N.V.

CVAC

3.67 USD

Patterson Companies, Inc. logo

Patterson Companies, Inc.

PDCO

22.63 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)